News
Current report No. 2/2021 – The National Centre for Research and Development recommended co-funding of the project dedicated to the development of a drug based on GPR40 receptor agonists in the treatment of neuropathic pain
Subject: The National Centre for Research and Development recommended co-funding of the project dedicated to the development of a drug based on GPR40 receptor agonists in the treatment of neuropathic pain Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information, time: 4:27 PM Content of the report: Management BoardRead more »
Celon Pharma at Top Picks by Trigon Investor Conference
On January 21, 2021, representatives of the Company’s Management Board will take part in the Top Picks by Trigon conference. Celon Pharma was among 21 companies recommended by Trigon DM in 2021.
Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression
Jan 8, 2020—Celon Pharma ($CLN.PL) today announced positive top-line results from a Phase II study of Falkieri (proprietary esketamine dry powder inhalation) in acute phase of treatment-resistant bipolar depression. View the webcast from TC See the presentation from the Meeting. In the trial, Falkieri met the primary endpoint with statistically significant reductions in MADRS total scoreRead more »
Current report No. 1/2021 – Positive results of the phase II clinical trial on Celon Pharma’s DPI esketamine in bipolar treatment-resistant depression [03KET2018]
Date prepared: 01/08/2021, 7:23 PM Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information. Content of the report: In relation to the current report No. 45/2020 regarding the date for the presentation of results of the phase II clinical trial on esketamine-based DPI drug (Falkieri) in bipolar treatment-resistant depression,Read more »
Celon Pharma at J.P. Morgan Annual Healthcare Conference DIGITAL 11-14 January 2021 .
This year, company taking meetings via the Bio Partnering platform during the week of the JP Morgan Healthcare Conference, but will also take part in meetings with foreign investors. Maciej Wieczorek, CEO of Celon Pharma: We have an intensive week of meetings and presentations ahead of us. This year, we use our presence at JPRead more »
Celon Pharma at Jefferies Virtual London Healthcare Conference
The Company’s representatives will take part in the largest pharmaceutical conference in Europe. Maciej Wieczorek, CEO of Celon Pharma S.A.: We are increasing the presence of our products abroad, building a strong position in the segment of inhalation products on the global pharmaceutical market; we are observing that companies from around the world are takingRead more »
The power of science, passion and innovation – video material and on line meeting
Video about R&D Centre with transcript.
The experts agree. The targeted drug against COVID currently developed by Celon Pharma might change the course of the disease.
Thanks to its cutting-edge, innovative approach, Celon Pharma fast-tracks confirmation of the efficacy of its treatment against SARS-COV-2. The new therapeutic approach designed by scientists at Celon Pharma combines the previously dispersed possible responses to the threat brought about by SARS-COV-2. That approach assumes shortening of the infection duration in affected patients and significant limitationRead more »
Results of the PI3K delta study developed by Celon Pharma in the prestigious PLOS Magazine
Results of the PI3K delta study developed by Celon Pharma – CPL302-253 – have been published in the prestigious PLOS Magazine Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma presents the results of the development of a preclinical, highly specific and safe PI3KRead more »